Dr Reddys Laboratories today said its net profit rose by over seven per cent to Rs 361 crore for the quarter ended June 30,primarily driven by North American revenues.
The companys net profit after tax stood at Rs 336 crore during the same quarter last fiscal year.
Net income from sales and services stood at Rs 2,845 crore during the quarter under discussion against Rs 2,541 crore an increase of 12 per cent.
Revenues from generic sales from North America recorded at Rs 1,090 crore up 37 per cent over last year.
Revenues from generic sales from India remained flat t Rs 350 crore due to the implantation of new Drug Pricing Policy 2012 which led to destocking in the trade coupled with the strike by Maharashtra traders,DRL said in a statement.